T1	Participants 95 215	asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer
T2	Participants 733 839	patients were randomly assigned (1:1) to receive enzalutamide 160 mg/day (n=872) or placebo (n=845) orally
